Does Amazon's latest healthcare move make the stock a buy?

Amazon has been trying to grow in the area of healthcare over the past couple of years.

| More on:
A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

It's clear that Amazon (NASDAQ: AMZN) wants to make its mark in the world of healthcare. The e-commerce giant opened a pharmacy service two years ago. And the company's trying to get a foothold in telemedicine, though it hasn't been easy. Amazon is shuttering its own service, Amazon Care, and is in the process of buying 1Life Healthcare (NASDAQ: ONEM), better known as One Medical -- a provider of in-person and virtual care.

But Amazon isn't stopping there. Its latest news is the creation of Amazon Clinic. This is an online service that lets you connect with clinicians for a variety of minor problems -- and get answers and prescriptions.

Let's take a closer look.

An El Dorado

Telemedicine represents a sort of El Dorado for players and potential players. The U.S. market is forecast to grow at a compound annual growth rate of more than 15% to nearly $25.9 billion by 2027, according to Polaris Market Research. Competition is high. And even a company with the resources of Amazon probably will have trouble beating a leader like Teladoc Health.

But Amazon's latest move may offer it an advantage in a niche market. Teladoc and others sell complete healthcare plans to corporations or individuals. But Amazon Clinic isn't a plan: It works like an online clinic -- and anyone can use it.

If you've ever spent hours waiting at a walk-in clinic, you'll probably understand the potential of Amazon's latest venture in healthcare. Instead of going to an in-person clinic if you have a minor problem like sinusitis or pink eye, you fill out a questionnaire about your symptoms on Amazon. Then it connects you with a medical professional who will send you a treatment plan.

The service isn't covered by insurance. The price varies depending on the state you live in and the clinic you choose -- but as an example, a consultation for pink eye costs $30 to $35 at a Florida clinic on the platform.

Amazon Clinic is sure to be an easier alternative than waiting around at a crowded walk-in clinic for treatment. So the service does have potential to fill a need -- and become successful.

Does this make Amazon a buy? First, let's answer another question: Will Amazon Clinic make Amazon a major player in healthcare? That's unlikely.

A niche market

Even though this looks like a positive step for Amazon, we're talking about a niche. The revenue opportunity is limited. And the business won't necessarily drive patients to Amazon Pharmacy -- the prescriptions can be filled anywhere.

So, I wouldn't buy Amazon shares for this move. I wouldn't even buy shares for the company's plan to grow in the healthcare market, because it's still way too early to predict whether Amazon can become a leader.

The company has already stumbled twice. As I mentioned earlier, it's closing Amazon Care as of the end of this year. And last year, it ended a healthcare joint venture with Berkshire Hathaway and JPMorgan Chase.

But note that I actually would buy shares of Amazon today. Rather than for its healthcare efforts, I'd buy them for its long-term growth potential in e-commerce and cloud computing.

Right now, higher inflation and general economic woes are weighing on those businesses. But these are temporary problems. Over the long term, Amazon has the market share and resources to thrive.

Today, the shares are trading at 1.9 times sales. That's around the lowest level by this measure since about 2015.

Amazon's ambitions in healthcare are something to watch. But the company's two main businesses are what make the stock a steal at today's levels. 

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Adria Cimino has positions in Amazon. JPMorgan Chase is an advertising partner of The Ascent, a Motley Fool company. John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Amazon, Berkshire Hathaway (B shares), JPMorgan Chase, and Teladoc Health. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended the following options: long January 2023 $200 calls on Berkshire Hathaway (B shares), short January 2023 $200 puts on Berkshire Hathaway (B shares), and short January 2023 $265 calls on Berkshire Hathaway (B shares). The Motley Fool Australia has recommended Amazon and Berkshire Hathaway (B shares). The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on International Stock News

A corporate team or board stands together and looks out the window.
International Stock News

Nasdaq Correction: I'd consider buying the dip on all "Magnificent Seven" stocks — Except this one

The index is down around 9% year to date and 13% from its December peak.

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
International Stock News

Prediction: Nvidia will soar over the next 5 years. Here's 1 reason why.

Nvidia has many irons in the fire that could all meaningfully contribute over the next five years.

Read more »

A man sits in deep thought with a pen held to his lips as he ponders his computer screen with a laptop open next to him on his desk in a home office environment.
International Stock News

Will Nvidia stock keep dropping in 2025?

Let's dig deeper to determine what the next nine months might have in store for the industry's leader.

Read more »

Woman looking at a phone with stock market bars in the background.
International Stock News

President Trump's trade war is here: Here's how investors can benefit

Tariff concerns have already unwound the S&P 500's post-election gains.

Read more »

AI written in blue on a digital chip.
International Stock News

Nasdaq correction: Time to buy the dip on Nvidia?

Let's take a look.

Read more »

Woman looks amazed and shocked as she looks at her laptop.
International Stock News

If you'd invested $10,000 in Amazon stock 25 years ago, here's how much you'd have today

How rewarding has the stock been?

Read more »

Warren Buffett
International Stock News

Warren Buffett just issued a stark warning to President Trump about the impact of tariffs. It couldn't be any clearer.

It's not too often that 94-year-old Warren Buffett comments on political matters.

Read more »

Happy man working on his laptop.
International Stock News

25% of Warren Buffett-led Berkshire Hathaway's $288 billion portfolio is invested in only 1 stock

Here are the factors that are likely attracting Buffett.

Read more »